News

Home  >  News > Iproteos, the first biotech to launch an equity crowdfunding campaign in Spain...

Iproteos, the first biotech to launch an equity crowdfunding campaign in Spain

Teresa Tarragó (in the center of the image) with the Iproteos team.

Teresa Tarragó (in the center of the image) with the Iproteos team.

15/07/2014

Recerca

The Catalan biotech Iproteos —a spin-off of the University of Barcelona (UB) and the Institute for Research in Biomedicine (IRB Barcelona) based at the Barcelona Science Park (PCB)— has launched an innovative funding campaign based on equity crowdfunding through the platform Creoentuproyecto.com. The aim of the initiative is to raise 100,000 euros to complete the non-regulatory preclinical stage of its compound IPR019. This compound is one of the 20 drugs in the world that are being developed to slow-down the progression of schizophrenia and revert the cognitive deficits of this condition.

Iproteos is a spin-off created in 2011 by two Catalan scientists who are pioneer in the field of therapeutic peptides: Ernest Giralt, professor from the Department of Organic Chemistry of UB, and Teresa Tarragó, from IRB Barcelona. The company was based on the transfer of a technology generated at UB and IRB Barcelona in which the Bosch i Gimpera Foundation (FBG) also participated.

 
Share this at:
| More |
  • Follow us:
  • Button to access University of Barcelona's Facebook profile
  • Button to access University of Barcelona's Twitter profile
  • ??? peu.google.alt ???
  • Button to access University of Barcelona's Youtube profile
  • Button to access University of Barcelona's RSS
Member of: Two Campuses of International Excellence logo del leru - League of European Research Universities logo del bkc - campus excel·lència logo del health universitat de barcelona campus

© Universitat de Barcelona